Latest "Placebo Hepatitis Virus Infection" News Stories

04:54 EST 22nd December 2014 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 9,900+

Extremely Relevant

[Comment] Hepatitis virus and HIV interactions

Because of shared routes of transmission, 5–25% of the 34 million people with HIV worldwide are co-infected with either hepatitis B virus (HBV), hepatitis C virus (HCV), or both, with the highest number of co-infections in low-income countries. The...

[Articles] HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort study

Screening for viral hepatitis is important in individuals diagnosed as HIV positive. Effective management for viral hepatitis should be integrated into HIV treatment programmes. Long-term data are needed about the effect of hepatitis co-infection on ...

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients af...

Hepatitis C Infection May Have 'Silver Lining' for Transplant Patients

WEDNESDAY, June 25, 2014 -- The liver-damaging hepatitis C virus may come with an unexpected benefit for patients who need a liver transplant due to the infection, a new European study reports. The virus appears to restrain a dangerous immune...

Should Direct-Acting Antiviral Agents Replace the Standard of Care for Hepatitis C Infection?

Lansdale, PA (PRWEB) September 15, 2014 For the 3.2 million people in the United States infected with the hepatitis C virus, disease management can be costly and debilitating. But are the new agents recently approved by the Food and Drug Administr...

Quantum Leaps, Microeconomics, and the Treatment of Patients With Hepatitis C and HIV Coinfection

Until very recently, patients with hepatitis C virus (HCV) infection were treated with pegylated-interferon administered weekly by subcutaneous injection plus ribavirin given orally twice daily. Over the last decade, however, by virtue of development...

Life expectancy among patients with chronic hepatitis C virus infection and cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced su...

Researchers discover how Hepatitis C virus persists for years

Hepatitis C virus (HCV) lingers in the human body for years, slowly damaging the liver and leading to liver diseases such as hepatitis, cirrhosis and liver cancer, which is often fatal. Research conducted at the University of North Carolina at Chapel...

BMS awards nine new grants to fight against hepatitis B and C in China and India

The Bristol-Myers Squibb Foundation has announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vuln...

Ciclofilin developing first drug for HCV/HIV-1 co-infection

Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity directed against both viruses. “Other companies are working on one or the other virus, so we would like to position ourselves as the company working on co-infection, where our […]

Medical News Today: Study identifies global prevalence of hepatitis C virus genotypes

Researchers from the UK have identified the worldwide prevalence of hepatitis C virus genotypes, in the hope it will help develop new treatment strategies for the infection.

Transmission of hepatitis C virus following antiviral treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV). Left untreated, infection results in serious complications such as cirrhosis of the liver and cancer. Many HCV-infected patients respond well to anti-viral therapy and...

Hepatitis A hospitalization rate declines in U.S.

The rate of hospitalization due to hepatitis A virus (HAV) infection has significantly declined in the U.S. from 2002 to 2011, new research shows. Findings show that older patients and those with chronic liver disease are most likely to be hospitaliz...

Enanta reports results from TURQUOISE-I study in chronic hepatitis C patients with HIV-1 co-infection

Enanta Pharmaceuticals, a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced at The Liver Meeting 2014 results from studies in chronic hepatitis C virus (HCV) p...

Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst

The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to mai...

Hepatitis A hospitalization rate declines in US

(Wiley) New research reports that the rate of hospitalization due to hepatitis A virus infection has significantly declined in the US from 2002 to 2011. Findings published in Hepatology, a journal of the American Association for the Study of Liver Di...

GlobalData Analyst: Harvoni Will Keep Gilead Atop Hepatitis C Virus Treatment Landscape

The recent US Food and Drug Administration (FDA) approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company ...

Bristol-Myers Squibb Foundation awards nine grants to support care for high-risk patients with hepatitis B and C in China and India

The Bristol-Myers Squibb Foundation today announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vu...

Well-Controlled Hepatitis C No Dent on Lifespan

Survival in patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who achieved sustained virological response is similar to that of the general population. Medscape Medical News

Antiviral treatment of hepatitis C

Hepatitis C virus (HCV) infection is a substantial health problem worldwide. Most patients infected with HCV remain chronically infected, with an increased risk of cirrhosis and hepatocellular...

FDA approves first combination pill to treat hepatitis C

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.

[Articles] Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTH

Once-daily grazoprevir plus elbasvir with or without ribavirin for 12 weeks in previously untreated HCV-mono-infected and HIV/HCV-co-infected patients without cirrhosis achieved SVR12 rates of 87–98%. These results support the ongoing phase 3 devel...

New Expensive Treatments for Hepatitis C Infection

Treatment of infection with hepatitis C virus (HCV) has changed substantially in the last 3 years, with new therapies now reaching cure rates (defined by sustained virologic response) higher than 95%. As little as 3 years ago, treatment involved an a...

Virus Infection Supports Organ Acceptance

A question of tolerance: Liver transplants in patients with hepatitis C Chronic hepatitis C virus infections are among the most common reasons for liver transplants. Because existing viruses also infect the new liver, the immune system is highly active there. Despite this, the new organ is not rejected, as scientists from the Helmholtz Zentrum München and the Technische Universität M&uum...

Hepatitis C ruled out as cause of mental impairment in HIV patients

(Washington University School of Medicine) Infection with the hepatitis C virus does not contribute to the problems in mental functions seen in many patients with long-term HIV infections, a new study reveals.


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks